- Exchange: London
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Hikma Pharmaceuticals PLC
+ Add to WatchlistHIK:LN
970.500 GBp 1.000 0.10%As of 11:35:06 ET on 05/24/2013.
Snapshot for Hikma Pharmaceuticals PLC (HIK)
| Open: | 971.000 | Day's Range: | 966.500 - 986.500 | Volume: | 231,351 |
|---|---|---|---|---|---|
| Previous Close: | 970.500 | 52wk Range: | 619.000 - 1,048.000 | 1-Yr Rtn: | +56.08% |
Key Statistics for HIK
| Current P/E Ratio (ttm) | 28.7391 |
|---|---|
| Estimated P/E(12/2013) | 20.0124 |
| Relative P/E vs. UKX | 1.7264 |
| Earnings Per Share (USD) (ttm) | 0.5109 |
| Est. EPS (USD) (12/2013) | 0.7330 |
| Est. PEG Ratio | 1.0157 |
| Market Cap (M GBP) | 1,916.59 |
| Shares Outstanding (M) | 197.48 |
| 30 Day Average Volume | 315,531 |
| Price/Book (mrq) | 3.4747 |
| Price/Sale (ttm) | 2.6006 |
| Dividend Indicated Gross Yield | 1.18% |
| Cash Dividend (USD) | 0.1000 |
| Last Dividend | 04/17/2013 |
| 5 Year Dividend Growth | 22.49% |
| Next Earnings Announcement | 08/21/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for HIK
Company Profile & Key Executives for HIK
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing, and marketing a range of both branded and non-branded generic and in-licensed pharmaceutical products. The Company's operations are conducted in the United States, the Middle East, and North Africa region, as well as Europe.
| Mazen Samih Taleb DarwazahVice Chairman/CEO:MENA | Said Sameeh Talib DarwazahChief Executive Officer |
| Khalid NabilsiChief Financial Officer | Michael Raya "Mike"President & CEO:US |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
HIK News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page